Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C17H20N2O2.ClH |
| Molecular Weight | 320.814 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2
InChI
InChIKey=JQIPVEBSCXNGIG-UHFFFAOYSA-N
InChI=1S/C17H20N2O2.ClH/c1-2-19(12-14-8-10-18-11-9-14)17(21)16(13-20)15-6-4-3-5-7-15;/h3-11,16,20H,2,12-13H2,1H3;1H
DescriptionCurator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/tropicamide.html
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/tropicamide.html
Tropicamide (Mydriacyl) is an anticholinergic used as a mydriatic.Tropicamide belongs to the group of medicines called anti-muscarinics. Tropicamide blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. By blocking these receptors, tropicamide produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia). Tropicamide is given as eye drops to dilate the pupil and relax the lens so that eye examinations can be carried out thoroughly.
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32320311 |
0.5 % single, ocular dose: 0.5 % route of administration: Ocular experiment type: SINGLE co-administered: PHENYLEPHRINE |
TROPICAMIDE plasma | Oryctolagus cuniculus population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
2.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8083562 |
400 μg single, ocular dose: 400 μg route of administration: Ocular experiment type: SINGLE co-administered: |
TROPICAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32320311 |
0.5 % single, ocular dose: 0.5 % route of administration: Ocular experiment type: SINGLE co-administered: PHENYLEPHRINE |
TROPICAMIDE plasma | Oryctolagus cuniculus population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30 min |
unknown |
TROPICAMIDE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
55% |
TROPICAMIDE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Ocular hypertension induced by tropicamide after treatment of the angle with argon laser]. | 1985 |
|
| Pupil dilatation assay by tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease. | 1996 Mar 22 |
|
| Identification of muscarinic receptor subtypes in RINm5F cells by means of polymerase chain reaction, subcloning, and DNA sequencing. | 1997 Sep |
|
| Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. | 1998 Nov |
|
| Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. | 2001 May |
|
| Neuronal nitric oxide synthase activity in rat urinary bladder detrusor: participation in M3 and M4 muscarinic receptor function. | 2005 Jul |
|
| Why patients with Alzheimer's disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus. | 2006 Jan |
|
| Activation of muscarinic cholinergic receptors inhibits giant neurones in the caudal pontine reticular nucleus. | 2006 Oct |
|
| Corticotropin-releasing factor inhibition of sheep fetal colonic contractility: mechanisms to prevent meconium passage in utero. | 2007 Apr |
|
| Transcriptional up-regulation of nitric oxide synthase II by nuclear factor-kappaB at rostral ventrolateral medulla in a rat mevinphos intoxication model of brain stem death. | 2007 Jun 15 |
|
| Muscarinic receptor-independent activation of cyclic adenosine monophosphate-dependent protein kinase in rostral ventrolateral medulla underlies the sympathoexcitatory phase of cardiovascular responses during mevinphos intoxication in the rat. | 2007 May |
|
| The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. | 2007 Oct |
|
| A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. | 2008 Apr |
|
| Temporal evolution of intraocular pressure elevation after pupillary dilation in pigment dispersion syndrome. | 2009 Mar |
|
| Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. | 2009 Sep 29 |
Patents
Sample Use Guides
Usual Adult Dose for Refraction
Cycloplegic Refraction:
-Instill 1 or 2 drops of the 1% solution into eye(s); repeat in 5 minutes.
Comment:
-An additional drop may be given if the examination is not done within 20 to 30 minutes. Usual Adult Dose for Pupillary Dilation
Fundoscopy:
-Instill 1 or 2 drops of 0.5% solution into eye(s) 15 or 20 minutes prior to examination.
Comments:
-Heavily pigmented irides may require higher strength or more doses.
Usual Pediatric Dose for Refraction
Cycloplegic Refraction:
-Instill 1 or 2 drops of the 1% solution into eye(s); repeat in 5 minutes.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
958623-78-4
Created by
admin on Sat Dec 16 10:21:10 GMT 2023 , Edited by admin on Sat Dec 16 10:21:10 GMT 2023
|
PRIMARY | |||
|
7YKJ7E29Z3
Created by
admin on Sat Dec 16 10:21:10 GMT 2023 , Edited by admin on Sat Dec 16 10:21:10 GMT 2023
|
PRIMARY | |||
|
10125724
Created by
admin on Sat Dec 16 10:21:10 GMT 2023 , Edited by admin on Sat Dec 16 10:21:10 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
